News

The collaboration is expected to be focused on improving data analysis and interpretation of high content screening, an enabling technology in the search for key cellular markers associated with human

Valeant develops and markets prescription and nonprescription pharmaceutical products. Valeant specializes in the neurology and dermatology therapeutic areas primarily in the US, Canada, Mexico, Brazil, Australia, and Central

As of the expiration of the tender offer, a total of approximately 73.17 shares of Memory common stock were tendered and not withdrawn, representing approximately 89% of outstanding

This candidate drug is a small molecule that Galapagos has developed in its selective androgen receptor modulator program and which has demonstrated successful proof of concept in animal

The transaction will give Meda exclusive rights to distribute Onsolis in all countries except Taiwan and South Korea for a one-time cash payment to BDSI of $3 million.

The FDA is expected to determine whether to accept the new drug application (NDA) for filing and consider the priority review request within 60 days. If approved, Acura

An agreement via the special protocol assessment (SPA) procedure is an agreement with the FDA that a Phase III clinical trial’s design (endpoints, sample size, control group and

The company noted that certain formalities must be completed before the reissue patent will be granted. The reissued patent will have the same force and effect as the

Mr Caloz joined CytRx in October 2007 and has served as the company’s chief accounting officer. Prior to joining CytRx, he served as CFO of publicly traded Occulogix